LOS ANGELES, June 27, 2024 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 15, 2024 Deadline for filing a lead plaintiff motion in the class action lawsuit on behalf of investors who purchased or otherwise acquired UnitedHealth Group Incorporated (“UnitedHealth” or the “Company”) (NYSE: UNH) Ordinary shares between 14 March 2022 and 27 February 2024inclusive (the “Lesson”).
If you have suffered a loss on your UnitedHealth investments or would like to learn about the possibility of making a claim to recover your loss under the U.S. securities laws, you may send your contact information to: www.glancylaw.com/cases/UnitedHealth-Group-Incorporated/You may also contact Charles H. Linehan of GPM at 310-201-9150, toll free at 888-773-9224, or via email at. [email protected] to learn more about your rights.
On February 27, 2024 The Wall Street Journal reported that the U.S. Department of Justice (“DOJ”) has launched an investigation into UnitedHealth into the relationship between its insurance division UnitedHealthcare and its healthcare services division Optum, which owns physician groups, among other things.
On this news, UnitedHealth’s stock price fell $27.04, or 5.1%, over two consecutive trading days to close at $498.28 per share on February 28, 2024, hurting investors.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations and prospects. Specifically, Defendants failed to disclose to investors that: (1) UnitedHealth never properly implemented firewalls between Optum and UnitedHealthcare, as it requires in its own policy and as it told the court in the antitrust case, the Department of Justice, and investors that it would do; (2) firewalls for certain business applications were never properly implemented; (3) despite representations to the contrary, there was never any meaningful technological separation between Optum and UnitedHealthcare that would have prevented the sharing of confidential customer information; and (4) as a result, Defendants’ positive statements about the Company’s business, operations and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Follow us for updates on LinkedIn, Þjórsárdenor Facebook.
If you purchased or otherwise acquired UnitedHealth common stock during the Class Period, you may move the Court no later than July 15, 2024 to request appointment as lead plaintiff in this putative class action. To become a member of the class, you do not need to take any action at this time; you may retain counsel of your choice or take no action and remain an absent class member. If you would like to learn more about this class action, or have any questions about this announcement or your rights or interests with respect to the pending class action, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at 310-201-9150, toll-free at 888-773-9224, by email at [email protected]or visit our website at glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under applicable laws and professional rules.
contacts
Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
[email protected]
glancylaw.com
